

Daniel F Hayes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8914311/publications.pdf>

Version: 2024-02-01

138
papers

23,435
citations

28190

55
h-index

12558

132
g-index

142
all docs

142
docs citations

142
times ranked

25263
citing authors

#	ARTICLE	IF	CITATIONS
1	Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer. <i>Oral Diseases</i> , 2022, 28, 193-201.	1.5	7
2	A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222. <i>Clinical Cancer Research</i> , 2022, 28, 611-617.	3.2	4
3	Muscle Mass Affects Paclitaxel Systemic Exposure and May Inform Personalized Paclitaxel Dosing. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	1.1	2
4	Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective. <i>Journal of Clinical Oncology</i> , 2022, 40, 1721-1731.	0.8	8
5	Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. <i>Npj Breast Cancer</i> , 2022, 8, 31.	2.3	7
6	Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection. <i>Molecular Oncology</i> , 2022, 16, 1969-1985.	2.1	8
7	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. <i>Modern Pathology</i> , 2022, 35, 1362-1369.	2.9	18
8	Ki67 as a Companion Diagnostic: Good or Bad News?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3796-3799.	0.8	10
9	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 390-399.	3.0	62
10	Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint. <i>Journal of Clinical Oncology</i> , 2021, 39, 238-248.	0.8	49
11	Inertial focusing of circulating tumor cells in whole blood at high flow rates using the microfluidic CTCKey device for CTC enrichment. <i>Lab on A Chip</i> , 2021, 21, 3559-3572.	3.1	25
12	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. <i>JAMA Oncology</i> , 2021, 7, 525-533.	3.4	65
13	Response to Zhang and Yang. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1597-1598.	3.0	4
14	Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. <i>Npj Breast Cancer</i> , 2021, 7, 77.	2.3	16
15	Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 116-123.	0.7	4
16	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6115-6123.	3.2	9
17	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021, 113, 808-819.	3.0	319
18	PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. <i>PLoS ONE</i> , 2021, 16, e0260124.	1.1	26

#	ARTICLE	IF	CITATIONS
19	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2336-2347.	13.9	363
20	Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. <i>Journal of the National Cancer Institute</i> , 2020, 112, 698-707.	3.0	48
21	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 505.	3.4	51
22	Completing the Translation. <i>Oncologist</i> , 2020, 25, 183-185.	1.9	0
23	Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. <i>Frontiers in Endocrinology</i> , 2020, 11, 35.	1.5	24
24	Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival. <i>British Journal of Cancer</i> , 2020, 122, 801-811.	2.9	52
25	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 1346-1366.	0.8	673
26	Clinical Applications of Circulating Tumor Cells in Breast Cancer. <i>Recent Results in Cancer Research</i> , 2020, 215, 147-160.	1.8	8
27	Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline <i>BRCA</i> -associated breast cancer (SWOG S1416).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1001-1001.	0.8	40
28	An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. <i>Modern Pathology</i> , 2019, 32, 59-69.	2.9	78
29	Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. <i>Pharmacogenomics</i> , 2019, 20, 571-580.	0.6	7
30	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	1.4	11
31	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	1.4	15
32	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405.	13.9	349
33	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. <i>Histopathology</i> , 2019, 75, 225-235.	1.6	74
34	Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1226-1234.	13.9	95
35	A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells. <i>Nature Communications</i> , 2019, 10, 1478.	5.8	80
36	Exemestane may be less detrimental than letrozole to bone health in women homozygous for the <i>UGT2B17*2</i> gene deletion. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 297-303.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study. <i>Clinical Cancer Research</i> , 2019, 25, 6089-6097.	3.2	46
38	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1242-1253.	1.2	120
39	Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1324-1331.	1.9	65
40	Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. <i>Cancer Research</i> , 2018, 78, 1110-1122.	0.4	85
41	Precision Medicine and Testing for Tumor Biomarkers—Are All Tests Born Equal?. <i>JAMA Oncology</i> , 2018, 4, 773.	3.4	17
42	Disseminated breast tumour cells: biological and clinical meaning. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 129-131.	12.5	42
43	Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. <i>Journal of Clinical Oncology</i> , 2018, 36, 617-623.	0.8	18
44	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , 2018, 36, 1631-1641.	0.8	668
45	Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 40.	2.3	36
46	Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 657-666.	1.1	34
47	Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5860-5872.	3.2	44
48	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.	13.9	1,558
49	Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation. <i>Clinical Breast Cancer</i> , 2017, 17, 350-355.e4.	1.1	10
50	Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 453-461.	1.1	8
51	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2017, 3, 29.	2.3	45
52	Integrative clinical genomics of metastatic cancer. <i>Nature</i> , 2017, 548, 297-303.	13.7	685
53	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. <i>New England Journal of Medicine</i> , 2017, 377, 1836-1846.	13.9	1,052
54	Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 659-668.	1.1	7

#	ARTICLE	IF	CITATIONS
55	Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5687-5695.	3.2	170
56	Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 411-419.	1.1	10
57	Delivery of Personalized Medicine With Precision. <i>JCO Precision Oncology</i> , 2017, 1, 1-3.	1.5	0
58	Learning From Our Patients. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-3.	1.0	0
59	American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce. <i>Journal of Clinical Oncology</i> , 2017, 35, 2576-2579.	0.8	41
60	Considerations for Implementation of Cancer Molecular Diagnostics Into Clinical Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 292-296.	1.8	7
61	Innovations in American Society of Clinical Oncology Practice Guideline Development. <i>Journal of Clinical Oncology</i> , 2016, 34, 3213-3220.	0.8	14
62	Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1134-1141.	1.1	13
63	ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. <i>Physiological Genomics</i> , 2016, 48, 688-698.	1.0	9
64	Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5864-5875.	3.2	99
65	Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance. <i>Molecular Oncology</i> , 2016, 10, 1078-1085.	2.1	43
66	Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. <i>Clinical Biochemistry</i> , 2016, 49, 1354-1360.	0.8	175
67	Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes. <i>Journal of Clinical Oncology</i> , 2016, 34, 3796-3802.	0.8	29
68	Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 87-95.	1.1	35
69	Is Breast Cancer a Curable Disease?. <i>Journal of Oncology Practice</i> , 2016, 12, 13-16.	2.5	6
70	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. <i>Nature Communications</i> , 2016, 7, 12791.	5.8	196
71	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. <i>Npj Breast Cancer</i> , 2016, 2, 16014.	2.3	109
72	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2016, 12, 384-389.	2.5	42

#	ARTICLE	IF	CITATIONS
73	Circulating Tumor Cells. <i>Advances in Experimental Medicine and Biology</i> , 2016, 882, 235-258.	0.8	69
74	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 1134-1150.	0.8	683
75	Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 589-595.	1.1	34
76	Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. <i>Clinical Cancer Research</i> , 2015, 21, 2771-2779.	3.2	78
77	Biomarker validation and testing. <i>Molecular Oncology</i> , 2015, 9, 960-966.	2.1	109
78	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2015, 33, 2695-2704.	0.8	279
79	Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 163-172.	1.1	23
80	An international study to increase concordance in Ki67 scoring. <i>Modern Pathology</i> , 2015, 28, 778-786.	2.9	195
81	Genome Medicine in Cancer: What's in a Name?. <i>Cancer Research</i> , 2015, 75, 1930-1935.	0.4	16
82	Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. <i>Molecular Oncology</i> , 2015, 9, 1868-1876.	2.1	29
83	Reply to F.-C. Bidard et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1623-1623.	0.8	1
84	Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences. <i>Breast</i> , 2015, 24, S6-S10.	0.9	13
85	Neoadjuvant Chemotherapy: What Are the Benefits for the Patient and for the Investigator?. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 36-39.	0.9	35
86	Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 263-273.	1.1	27
87	Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2487-2498.	3.2	112
88	Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju034-dju034.	3.0	47
89	Molecular Testing in Breast Cancer. <i>Annual Review of Medicine</i> , 2014, 65, 95-110.	5.0	47
90	Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. <i>Journal of Clinical Oncology</i> , 2014, 32, 3483-3489.	0.8	543

#	ARTICLE	IF	CITATIONS
91	Effect of Estrogen Depletion on Pain Sensitivity in Aromatase Inhibitor-Treated Women With Early-Stage Breast Cancer. <i>Journal of Pain</i> , 2014, 15, 468-475.	0.7	28
92	Pretreatment worry and neurocognitive responses in women with breast cancer.. <i>Health Psychology</i> , 2014, 33, 222-231.	1.3	62
93	An International Ki67 Reproducibility Study. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1897-1906.	3.0	498
94	Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. <i>Nature Nanotechnology</i> , 2013, 8, 735-741.	15.6	487
95	Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. <i>Molecular Oncology</i> , 2013, 7, 680-692.	2.1	82
96	From genome to bedside: Are we lost in translation?. <i>Breast</i> , 2013, 22, S22-S26.	0.9	13
97	Breaking a Vicious Cycle. <i>Science Translational Medicine</i> , 2013, 5, 196cm6.	5.8	112
98	OMICS-based personalized oncology: if it is worth doing, it is worth doing well!. <i>BMC Medicine</i> , 2013, 11, 221.	2.3	18
99	Targeting Adjuvant Chemotherapy: A Good Idea That Needs to Be Proven!. <i>Journal of Clinical Oncology</i> , 2012, 30, 1264-1267.	0.8	59
100	Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting. <i>Journal of Clinical Oncology</i> , 2012, 30, 4223-4232.	0.8	173
101	Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 367, 435-444.	13.9	352
102	Biospecimen Reporting for Improved Study Quality. <i>Biopreservation and Biobanking</i> , 2011, 9, 57-70.	0.5	106
103	Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1656-1664.	3.0	1,505
104	Biomarker studies: a call for a comprehensive biomarker study registry. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 171-176.	12.5	106
105	Disease related indicators for a proper choice of adjuvant treatments. <i>Breast</i> , 2011, 20, S162-S164.	0.9	1
106	Steady Progress against HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 1336-1338.	13.9	14
107	Bevacizumab Treatment for Solid Tumors. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 506.	3.8	51
108	Response: Re: Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1559-1560.	3.0	2

#	ARTICLE	IF	CITATIONS
109	Predictive and prognostic markers in cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 130-2.	0.3	1
110	Circulating Tumor Cells. <i>Progress in Molecular Biology and Translational Science</i> , 2010, 95, 95-112.	0.9	37
111	Contribution of biomarkers to personalized medicine. <i>Breast Cancer Research</i> , 2010, 12, S3.	2.2	18
112	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 907-922.	1.2	697
113	Cyclin E as a prognostic factor: What is the question?. <i>Cell Cycle</i> , 2009, 8, 965-965.	1.3	1
114	Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1446-1452.	3.0	899
115	Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?. <i>Breast</i> , 2009, 18, S131-S134.	0.9	4
116	Cost-effective analyses in Breast Cancer Research and Treatment. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 221-222.	1.1	1
117	Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 365-372.	1.1	200
118	Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer?. <i>Clinical Cancer Research</i> , 2008, 14, 3646-3650.	3.2	104
119	Markers of endocrine sensitivity. <i>Breast Cancer Research</i> , 2008, 10, S18.	2.2	7
120	HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1496-1506.	13.9	531
121	Follow-up of Patients with Early Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 356, 2505-2513.	13.9	83
122	Angiogenesis as targeted breast cancer therapy. <i>Breast</i> , 2007, 16, 17-19.	0.9	45
123	Adjuvant Systemic Therapy for Elderly Women with Breast Cancer. <i>Women's Health</i> , 2006, 2, 75-87.	0.7	0
124	Uses and Abuses of Tumor Markers in the Diagnosis, Monitoring, and Treatment of Primary and Metastatic Breast Cancer. <i>Oncologist</i> , 2006, 11, 541-552.	1.9	132
125	Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival. <i>Clinical Cancer Research</i> , 2006, 12, 4218-4224.	3.2	937
126	Prognostic and predictive factors revisited. <i>Breast</i> , 2005, 14, 493-499.	0.9	93

#	ARTICLE	IF	CITATIONS
127	RESPONSE: Re: Playing the Old Piano: Another Tune for Endocrine Therapy. Journal of the National Cancer Institute, 2004, 96, 557-557.	3.0	0
128	Tamoxifen: Dr. Jekyll and Mr. Hyde?. Journal of the National Cancer Institute, 2004, 96, 895-897.	3.0	24
129	Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. New England Journal of Medicine, 2004, 351, 781-791.	13.9	4,124
130	Markers of increased risk for failure of adjuvant therapies. Breast, 2003, 12, 543-549.	0.9	17
131	c-erbB-2 in breast cancer: Development of a clinically useful marker. Seminars in Oncology, 2002, 29, 231-245.	0.8	119
132	2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*. Journal of Clinical Oncology, 2001, 19, 1865-1878.	0.8	770
133	The role of c-erbB-2 as a predictive factor in breast cancer. Breast Cancer, 2001, 8, 171-183.	1.3	32
134	Prognostic factors in breast cancer: current and new predictors of metastasis. Journal of Mammary Gland Biology and Neoplasia, 2001, 6, 375-392.	1.0	184
135	Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2000, 18, 2710-2717.	0.8	108
136	Circulating tumor markers in breast cancer: Accepted utilities and novel prospects. Breast Cancer Research and Treatment, 1998, 52, 239-259.	1.1	74
137	Circulating Tumor Markers in Breast Cancer. Hematology/Oncology Clinics of North America, 1989, 3, 653-674.	0.9	27
138	Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. Journal of Clinical Oncology, 0, , .	0.8	0